Antibody-Chemo cocktail targets tough childhood cancer
NCT ID NCT03189706
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether adding an experimental antibody called Hu3F8 to a standard chemotherapy regimen (irinotecan and temozolomide) plus a immune-boosting drug (GM-CSF) is safe and effective for children with high-risk neuroblastoma. The trial enrolls patients whose neuroblastoma is defined as high-risk based on stage and genetic features. Researchers will monitor side effects and measure how well the tumor responds over four cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hu3F8 (antibody), irinotecan, temozolomide, and GM-CSF
- What this could lead to
- If successful, this combination could offer a new treatment option for children with high-risk neuroblastoma, potentially improving response rates.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination may cause significant side effects, and it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA (NB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.